|
Re: Breaking Down Barriers: BiOasis Technologies Promises Breakthrough Brain Drug Delivery
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jun 19, 2018 03:59PM
|
|
Re: Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the ASCO Conference
|
2
|
Zenith Epigenetics
|
Jun 21, 2022 11:57AM
|
|
Re: Gasoline
|
2
|
Zenith Epigenetics
|
Jan 30, 2017 08:34PM
|
|
Re: Not adding up!
|
2
|
Zenith Epigenetics
|
Nov 15, 2021 12:43PM
|
|
Re: Tired and dissappointed ( not shock ) ...
|
2
|
Resverlogix Corp.
|
May 19, 2016 02:14PM
|
|
RE: TFSA
|
2
|
Zenith Epigenetics
|
Nov 24, 2022 04:01PM
|
|
Re: AGM Voting
|
2
|
Zenith Epigenetics
|
Oct 18, 2022 01:09PM
|
|
Re: Zenith trial partners
|
2
|
Zenith Epigenetics
|
Feb 01, 2023 08:07PM
|
|
Re: Zenith trial partners
|
2
|
Zenith Epigenetics
|
Feb 01, 2023 11:14PM
|
|
Re: Update from IR -- Eversana paused?
|
2
|
Resverlogix Corp.
|
Dec 22, 2022 11:32AM
|
|
Re: Clinical trials query results
|
2
|
Zenith Epigenetics
|
Apr 08, 2021 10:23AM
|
|
Re: Some history
|
2
|
Resverlogix Corp.
|
Jan 25, 2023 01:21PM
|
|
Re: Eligibility for registered accounts in Canada
|
2
|
Zenith Epigenetics
|
Aug 17, 2018 01:16PM
|
|
Re: Eligibility for registered accounts in Canada
|
2
|
Zenith Epigenetics
|
Aug 17, 2018 01:34PM
|
|
Re: Eligibility for registered accounts in Canada
|
2
|
Zenith Epigenetics
|
Aug 17, 2018 01:45PM
|
|
Re: rndbtl on IV - Sanofi's relationship with Rothschild
|
2
|
Resverlogix Corp.
|
Jan 14, 2019 06:15PM
|
|
Re: IR
|
2
|
Resverlogix Corp.
|
Jan 18, 2023 02:56PM
|
|
Re: rndbtl on IV - Sanofi's relationship with Rothschild
|
2
|
Resverlogix Corp.
|
Jan 14, 2019 06:28PM
|
|
Re: Stability
|
2
|
Resverlogix Corp.
|
Nov 22, 2015 07:14PM
|
|
Re: New Docs
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jul 30, 2016 06:09PM
|
